Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial-Reference-Cited by-同舟云学术

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Published:2017-03 Issue:3 Volume:76 Page:405-417
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Blauvelt Andrew,Papp Kim A.,Griffiths Christopher E.M.,Randazzo Bruce,Wasfi Yasmine,Shen Yaung-Kaung,Li Shu,Kimball Alexa B.

Publisher

Elsevier BV

Subject

Dermatology

Reference46 articles.

1. World Health Organization. Global report on psoriasis. Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf. Accessed May 31, 2016.

2. Long-term management of scalp psoriasis: perspectives from the international psoriasis council;Kragballe;J Dermatol Treat,2013

3. Nail psoriasis: a review;Tan;Am J Clin Dermatol,2012

4. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis;Chung;J Am Acad Dermatol,2014

5. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas;Wozel;Clin Dermatol,2008

Cited by 720 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study;Clinical Pharmacology in Drug Development;2024-09-04

2. Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection;Cureus;2024-09-03

3. Newer Therapies in Rheumatology;Medical Clinics of North America;2024-09

4. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

5. Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy;JID Innovations;2024-09